[Prognosis in multiple sclerosis].
Prognosis of the natural course of multiple sclerosis is most often measured on Kurtzke's "expanded disability status scale" (EDSS), a non-linear scale over 20 steps, heavily weighted on mobility. Optic neuritis and sensory disturbances as initial symptoms, lower age at onset of the disease, female sex and a longer interval between relapses are indicators of a more favorable prognosis. As a rule, disability as measured on this scale 5 years after onset corresponds to 3/4 of the disability status after 15 years. The number of relapses diminishes naturally over the course of the disease. Presence and extent of lesions on the initial MRI of the brain in clinically isolated syndromes are valuable predictors of dissemination of the disease process over the following 5-10 years. New therapies (e.g. interferon beta 1b and 1a, copolymer 1) reduce relapse frequency by 1/3 and diminish the extent of pathological lesions in brain MRI, but fail to show (as yet) significant influence on disability.
Kesselring
J
J
Rehabilitationszentrum Valens.
D000328:Adult; D000367:Age Factors; D001921:Brain / Q000473:pathology; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000628:therapy; D010455:Peptides / Q000627:therapeutic use; D011108:Polymers / Q000627:therapeutic use; D011379:Prognosis; D012737:Sex Factors
D007166:Immunosuppressive Agents; D010455:Peptides; D011108:Polymers; D000068717:Glatiramer Acetate; D007372:Interferons
Die Prognose der Multiplen Sklerose.